GeneMetrics unveils a customizable genomics platform unifying lifestyle, clinical & diagnostic testing. Go beyond white-label with auditable science, full data GeneMetrics unveils a customizable genomics platform unifying lifestyle, clinical & diagnostic testing. Go beyond white-label with auditable science, full data

GeneMetrics Platform Addresses Fragmented Genetics Market with Fully Customizable Testing Solutions

3 min read

The genetics marketplace presents health companies, practitioners, and researchers with a difficult choice between consumer-friendly kits lacking clinical depth and inflexible, overly technical clinical platforms. This fragmentation forces clients to assemble incomplete solutions from multiple providers, leading to disjointed patient experiences characterized by multiple tests, portals, and confusing reports. GeneMetrics was developed to resolve this industry-wide challenge by providing the first platform to unify lifestyle, clinical, diagnostic, and advanced genetic testing in one location.

Unlike typical white-label solutions that offer generic, one-size-fits-all models, GeneMetrics functions as a custom testing product development company where every aspect—from kit design and packaging to wet-lab testing and data reporting—can be tailored to a client’s specific vision, brand identity, and clinical philosophy. The platform’s fundamental promise is limitless customization, supported by one of the largest libraries of report elements and scientific topics, featuring thousands of validated options. Clients can create offerings ranging from simple to highly advanced, integrating genetics, bloodwork, and lifestyle factors into single, cohesive patient reports.

GeneMetrics provides extensive sequencing and laboratory technology options, including bead-chip genotyping arrays, clinical-grade Whole Exome Sequencing (WES), clinical-grade Whole Genome Sequencing (WGS), PCR and PGx panels, and testing for epigenetics, blood, urine, saliva, and microbiomes. This guarantees flexibility across consumer lifestyle kits, clinical diagnostics, and enterprise research. The platform also features a fully customizable recommendation engine that prioritizes clarity over quantity, generating actionable steps for supplements, diet, lifestyle modifications, or medications to improve patient outcomes and practitioner efficiency.

Scientific integrity is paramount, with every methodology thoroughly validated and fully auditable. The platform includes a dedicated auditing system, making it a transparent solution, and incorporates machine learning algorithms referencing over 140,000 peer-reviewed studies. GeneMetrics adheres to high compliance standards including HIPAA, GDPR, SOC 2 Type 2, and ISO27001, with data protected through multi-layer encryption. Clients maintain 100 percent ownership of their data, with many opting to transfer ownership directly to patients. For transparency, GeneMetrics provides live compliance policies and monitoring at https://trust.genemetrics.com.

The platform is engineered for rapid scalability, supporting turn-key logistics management from boutique clinics to large-scale genomics initiatives. While confidentiality agreements prevent disclosing client names, GeneMetrics is a trusted backend provider for leading genomics and health companies globally. By merging genetics, epigenetics, blood, microbiome, and lifestyle data into one cohesive ecosystem, the company is facilitating a transition from reactive medicine to personalized, preventive care. More information about the company is available at https://genemetrics.com.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by Press Services. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is GeneMetrics Platform Addresses Fragmented Genetics Market with Fully Customizable Testing Solutions.

The post GeneMetrics Platform Addresses Fragmented Genetics Market with Fully Customizable Testing Solutions appeared first on citybuzz.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Strategy to initiate a bitcoin security program addressing quantum uncertainty

Strategy to initiate a bitcoin security program addressing quantum uncertainty

Markets Share Share this article
Copy linkX (Twitter)LinkedInFacebookEmail
Strategy to initiate a bitcoin security prog
Share
Coindesk2026/02/06 18:21
Strategic Shift Impacts Crypto Trading Landscape

Strategic Shift Impacts Crypto Trading Landscape

The post Strategic Shift Impacts Crypto Trading Landscape appeared on BitcoinEthereumNews.com. Bybit Delists MILK: Strategic Shift Impacts Crypto Trading Landscape
Share
BitcoinEthereumNews2026/02/06 18:01
SEC clears framework for fast-tracked crypto ETF listings

SEC clears framework for fast-tracked crypto ETF listings

The post SEC clears framework for fast-tracked crypto ETF listings appeared on BitcoinEthereumNews.com. The Securities and Exchange Commission has approved new generic listing standards for spot crypto exchange-traded funds, clearing the way for faster approvals. Summary SEC has greenlighted new generic listing standards for spot crypto ETFs. Rule change eliminates lengthy case-by-case approvals, aligning crypto ETFs with commodity funds. Grayscale’s Digital Large Cap Fund and Bitcoin ETF options also gain approval. The U.S. SEC has approved new generic listing standards that will allow exchanges to fast-track spot crypto ETFs, marking a pivotal shift in U.S. digital asset regulation. According to a Sept. 17 press release, the SEC voted to approve rule changes from Nasdaq, NYSE Arca, and Cboe BZX, enabling them to list and trade commodity-based trust shares, including those holding spot digital assets, without submitting individual proposals for each product. A streamlined path for crypto ETFs Under the new rules, an ETF can be listed without SEC sign-off if its underlying asset trades on a market with surveillance-sharing agreements, has active CFTC-regulated futures contracts for at least six months, or already represents at least 40% of an existing listed ETF. This brings crypto ETFs in line with traditional commodity-based funds under Rule 6c-11, eliminating a process that could take up to 240 days. SEC chair Paul Atkins said the move was designed to “maximize investor choice and foster innovation” while ensuring the U.S. remains the leading market for digital assets. Jamie Selway, director of the division of trading and markets, called the framework “a rational, rules-based approach” that balances access with investor protection. First products already approved Alongside the new standards, the SEC cleared the listing of the Grayscale Digital Large Cap Fund, which tracks spot assets based on the CoinDesk 5 Index. It also approved trading of options tied to the Cboe Bitcoin U.S. ETF Index and its mini version, with…
Share
BitcoinEthereumNews2025/09/18 14:04